a

Clinical Studies

Magmaris® RMS’ clinical body of evidence keeps growing with new data from BIOSOLVE-IV of the first cohort with 1,075 patients at 24 months follow-up.

BIOSOLVE-IV 24 months

24-month follow-up of first cohort with 1,075 patients1

BIOSOLVE-IV registry - Results of the first cohort of 1,075 patients

Prof. Dr. Jan Torzewski, Cardiovascular Center Oberallgaeu-Kempten, Oberallgaue, Germany presents the results

BIOSOLVE-IV TLF rate
BIOSOLVE-IV registry - Results of the first cohort of 1,075 patients

Prof. Dr. Jan Torzewski, Cardiovascular Center Oberallgaeu-Kempten, Oberallgaue, Germany presents the results

1. Torzewski J. Safety and performance of Magmaris at 24-month follow-up of BIOSOLVE-IV. Presented at: eEuroPCR; 2021; virtual congress. ClinicalTrials.gov: NCT02817802;  2. Target Lesion Failure (TLF) defined as a composite of Cardiac Death, Target-Vessel Myocardial Infarction (TV-MI), emergent Coronary Artery Bypass Grafting (CABG) and Clinically-Driven Target Lesion Revascularization (CD-TLR); Peri-procedural MI according to SCAI definition and spontaneous MI according to the Extended Historical definition. All events have been adjudicated by an independent clinical event committee. BIOSOLVE-IV data based on Kaplan-Meier failure estimate analysis including censored observations.

Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.
​​​​​​​Magmaris is currently not available in the US.

© 2021 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.